Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ARCUTIS BIOTHERAPEUTICS INC.
ARQT | US
24.82
USD0.82
3.42%
ARQT | US
About ARCUTIS BIOTHERAPEUTICS INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
24.82
Open
23.92
High
24.93
Low
23.76
Arcutis Biotherapeutics Inc. a biopharmaceutical company focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151 a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154 a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252 a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255 a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234 a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis Inc. and changed its name to Arcutis Biotherapeutics Inc. in October 2019. Arcutis Biotherapeutics Inc. was incorporated in 2016 and is headquartered in Westlake Village California.
View LessARQT | US
Risk
64.4
Sharpe
1.09
Luna's Score
40/100
Recommendation
Sell
Luna says (ARQT | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
69.1%1 month
64.4%3 months
48.5%6 months
63.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.95
Debt to equity
1.11
Debt to assets
0.47
Ent. to EBITDA
-2.04
Ent. to rev.
7.23
PEG
-
Other Fundamentals
EBITDA
-178.29M
MarketCap
2.90B
MarketCap(USD)
2.90B
Div. yield
-
Op. margin
-162.28
Erngs. growth
-
Rev. growth
494.60
Ret. on equity
-148.92
Short ratio
14.56
Short perc.
28.72
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
5.95
Range1M
5.95
Range3M
8.92
Volumes: Market Activity
Rel. volume
0.74
Price X volume
25.71M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.04 | 0.53 | Cheaper |
| Ent. to Revenue | 7.23 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.95 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 48.55 | 72.80 | Lower Risk |
| Debt to Equity | 1.11 | -1.23 | Expensive |
| Debt to Assets | 0.47 | 0.25 | Expensive |
| Market Cap | 2.90B | 3.66B | Emerging |
